Results 91 to 100 of about 30,839 (241)

Detection of derivative 9 deletion by BCR-ABL fluorescence in-situ hybridization signal pattern to evaluate treatment response in CML patients [PDF]

Archive of Oncology, 2009
Background: To evaluate prognostic effect of submicroscopic deletions involving breakage and fusion points of the derivative chromosome 9 and 22 in chronic myeloid leukemia in untreated patients and their follow up samples to correlate with disease ...
Bakshi Sonal R., Shah Pankaj M., Shukla Shilin N., Dalal Esha N., Iyer Ramesh R., Brahmbhatt Manisha M., Gajjar Sarju B., Trivedi Pina J., Patel Beena P.   +8 more
doaj   +1 more source

Drug‐Induced Liver Injury Associated With Emerging Cancer Therapies

Liver International, Volume 45, Issue 2, February 2025.
ABSTRACT Targeted therapies and immunotherapies have shown great promise as best‐in‐class treatments for several cancers with respect to efficacy and safety. While liver test abnormalities are rather common in patients treated with kinase inhibitors or immunotherapy, events of severe hepatotoxicity in these patients are rare in comparison with those ...
Piotr Chodup, Sophia L. Samodelov, Michele Visentin, Gerd A. Kullak‐Ublick   +3 more
wiley   +1 more source

Dasatinib and azacitidine followed by haploidentical stem cell transplant for chronic myeloid leukemia with evolving myelodysplasia: A case report and review of treatment options. [PDF]

, 2017
BACKGROUND: CML presenting with a variant Philadelphia translocation, atypical BCR-ABL transcript, additional chromosomal aberrations, and evolving MDS is uncommon and therapeutically challenging.
Ottmann, Oliver
core   +2 more sources

P210 and P190 BCR-ABL fusion transcripts variants frequencies among Philadelphia chromosome-positive chronic myeloid leukemia in Sudan

International Journal of Biomedical Research, 2018
Breakpoint cluster region-abelson (BCR-ABL) leukemic fusion gene types in chronic myeloid leukemia (CML) correlate with the disease clinical course and outcome.
Abdalla Abdelrahman Ahmed Elnour, M. A. Abdalla   +1 more
semanticscholar   +1 more source

Elevated CA15‐3 Levels in Myeloid Disorders: Clinicopathological Correlation

European Journal of Cancer Care, Volume 2025, Issue 1, 2025.
Background: Serum tumor markers are beneficial to patients with advanced cancer because they help in early diagnosis, determining prognosis, predicting response to certain medications, and monitoring therapy. The prognostic value of cancer antigen 15‐3 (CA15‐3) serum‐level changes in breast cancer is very well established.
Samah Saharti, Mohamad Qari, Sourav Panja   +2 more
wiley   +1 more source

Serum concentrations of nitrite and malondialdehyde as markers of oxidative stress in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

Revista Brasileira de Hematologia e Hemoterapia, 2012
BACKGROUND: Chronic myeloid leukemia is a neoplasm characterized by clonal expansion of hematopoietic progenitor cells resulting from the (9:22)(q34,11) translocation.
Maria Juracy Petrola, Alana Joselina Montenegro de Castro, Maria Helena da Silva Pitombeira, Maritza Cavalcante Barbosa, Acy Telles de Souza Quixadá, Fernando Barroso Duarte, Romelia Pinheiro Gonçalves   +6 more
doaj   +1 more source

AXL promotes malignant phenotypes in tumor cells and might be a potential antitumor target of natural products

Advanced Chinese Medicine, Volume 1, Issue 4, Page 179-189, December 2024.
Abstract AXL belongs to the TAM receptor tyrosine kinase family. Relying on binding its high‐affinity ligand—growth arrest‐specific protein 6 (Gas6)—AXL plays an important role in tumor initiation and progression. Traditional Chinese Medicine (TCM) has been clinically used in tumor treatment for a long time, and remarkable therapeutic efficacy has been
Yuan Yuan, Shan Wang, Jia‐Lei Fu, Xin‐Xin Deng, Yang Guo, Zheng‐Wang Guo, Shu‐Yan Han   +6 more
wiley   +1 more source

A Case of Hepatocellular Carcinoma after Treatment for Chronic Myeloid Leukemia in a Patient without Liver Disease

Case Reports in Oncology
Introduction: Chronic myeloid leukemia (CML) is a myeloproliferative disease caused by the reciprocal translocation of chromosomes 9 and 22, which leads to a chimeric gene product known as BCR-ABL.
Darshankumar M. Raval, Ricardo J. Pagán, Shayan Butt, Libardo Rueda Prada   +3 more
doaj   +1 more source

Diversity of breakpoints of variant Philadelphia chromosomes in chronic myeloid leukemia in Brazilian patients

Revista Brasileira de Hematologia e Hemoterapia, 2015
Background: Chronic myeloid leukemia is a myeloproliferative disorder characterized by the Philadelphia chromosome or t(9;22)(q34.1;q11.2), resulting in the break-point cluster regionAbelson tyrosine kinase fusion gene, which encodes a constitutively ...
Maria de Lourdes Lopes Ferrari Chauffaille, Ana Carolina de Almeida Bandeira, Aline Schiavoni Guarnieri da Silva   +2 more
doaj   +1 more source

Inhibition of MDM2 by nilotinib contributes to cytotoxicity in both Philadelphia-positive and negative acute lymphoblastic leukemia. [PDF]

PLoS ONE, 2014
Nilotinib is a selective BCR-ABL tyrosine kinase inhibitor related to imatinib that is more potent than imatinib. Nilotinib is widely used to treat chronic myelogenous leukemia (CML) and Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL). The
Hailong Zhang, Lubing Gu, Tao Liu, Kuang-Yueh Chiang, Muxiang Zhou   +4 more
doaj   +1 more source